TABLE 1.
Patient characteristics for all patients and for patients classified according to severity of airway hyper-responsiveness (AHR)
| n (% female) | Age*, years |
Distance*, m |
FEV1% predicted (%) | ICS†‡, μg | LABA‡, μg | PC20§, mg/mL | ||
|---|---|---|---|---|---|---|---|---|
| From major roads | From highways | |||||||
| All | 2145 (64) | 46 (23) | 168 (229) | 265 (239) | 95.8 (20.1) | 0 (0, 2400) | 0 (0,200) | 2.95 (5.51) |
| AHR (PC20, mg/mL) | ||||||||
| Severe (<0.25) | 93 (72) | 41 (29) | 189 (203) | 188 (159) | 84.1 (18.6) | 0 (800,1600) | 0 (0, 200) | 0.04 (0.11) |
| Moderate (0.25–2.0) | 231 (73) | 46 (24) | 140 (210) | 229 (397) | 84.6 (17.3) | 0 (500,1600) | 0 (0,100) | 1.05 (0.91) |
| Mild (2.1–16.0) | 458 (69) | 46 (23) | 169 (229) | 279 (187) | 92.8 (17.6) | 0 (250,1600) | 0 (0,100) | 5.60 (5.50) |
| Normal (>16.0) | 1361 (60) | 48 (23) | 162 (235) | 251 (235) | 98.9 (19.0) | 0 (0, 2400) | 0 (0,100) | 16.00 (0.0) |
*
Data presented as as median (interquartile range [IQR]);
†
Fluticasone equivalent;
‡
Dosage data presented as median (IQR, full range);
§
Data presented as median (IQR) for PC20 <16 mg/mL. FEV1 Forced expiratory volume in 1 s; ICS Inhaled corticosteroid; LABA Long-acting beta2-agonist; PC20 Provocative concentration of methacholine causing a 20% decline in FEV1